Further suppression of immune response in renal allograft recipients infected with hepatitis C

2001 ◽  
Vol 33 (7-8) ◽  
pp. 3645 ◽  
Author(s):  
V.K Rao ◽  
M Plummer ◽  
A Khanna
2011 ◽  
Vol 7 (10) ◽  
pp. e1002289 ◽  
Author(s):  
Noëlla Arnaud ◽  
Stéphanie Dabo ◽  
Daisuke Akazawa ◽  
Masayoshi Fukasawa ◽  
Fumiko Shinkai-Ouchi ◽  
...  

2021 ◽  
Author(s):  
Haidi Karam-Allah Ramadan ◽  
Gamal Badr ◽  
Nancy K Ramadan ◽  
Aml Sayed

Abstract The use of direct-acting antivirals (DAAs) therapy for the treatment of hepatitis C virus (HCV) results in a high sustained virological response (SVR) and subsequently alters liver immunologic environment. However, hepatocellular carcinoma (HCC) may occur after DAAs treatment. We aimed to clarify changes of immune responses, PI3K/AKT and JAK/STAT signaling pathways in HCV-induced liver diseases and HCC following DAAs treatment. Four cohorts are classified as chronic HCV patients, HCV-related cirrhosis without HCC, HCV-related cirrhosis and HCC, and healthy control group. The patient groups were further divided into treated or untreated with DAAs with SVR12. Increased percentages of CD3, CD8 and CD4, decreased CD4/FoxP3/CD25, CD8/PD-1 and CD19/PDL-1 were found in DAAs-treated patients in the three HCV groups. Following DAAs therapy, the levels of ROS, IL-1β, IL-6, IL-8 and TNF-α were significantly decreased in the three HCV groups. Treated HCV patients showed up regulation of p-AKT and p-STAT5 and down regulation of p-STAT3, HIF-1α and COX-2. In conclusion, DAAs enhance the immune response in chronic HCV and liver cirrhosis, hence our study is the first to show change in PI3K/AKT and JAK/STAT signaling pathways in different HCV-induced liver diseases after DAAs. In chronic HCV, DAAs have better impact on the immune response while in liver cirrhosis not all immune changes were prominent.


Viruses ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1103
Author(s):  
Keyla Santos Guedes de Sá ◽  
Ednelza da Silva Graça Amoras ◽  
Simone Regina Souza da Silva Conde ◽  
Maria Alice Freitas Queiroz ◽  
Izaura Maria Vieira Cayres-Vallinoto ◽  
...  

An inefficient immune response against the hepatitis C virus (HCV), combined with viral evasion mechanisms, is responsible for the chronicity of infection. The need to evaluate the innate mechanisms of the immune response, such as TLR3 and IFN-λ3, and their relationship with the virus–host interaction is important for understanding the pathogenesis of chronic hepatitis C. The present study aimed to investigate the gene expressions of TRL3 and IFNL3 in liver tissue, seeking to evaluate whether these could be potential biomarkers of HCV infection. A total of 23 liver biopsy samples were collected from patients with chronic HCV, and 8 biopsies were collected from healthy control patients. RNA extraction, reverse transcription and qPCR were performed to quantify the relative gene expressions of TLR3 and IFNL3. Data on the viral load; AST, ALT, GGT and AFP levels; and the viral genotype were collected from the patients′ medical records. The intrahepatic expression of TLR3 (p = 0.0326) was higher in chronic HCV carriers than in the control group, and the expression of IFNL3 (p = 0.0037) was lower in chronic HCV carriers than in the healthy control group. The expression levels of TLR3 (p = 0.0030) and IFNL3 (p = 0.0036) were higher in the early stages of fibrosis and of necroinflammatory activity in the liver; in contrast, TLR3 and IFNL3 expressions were lower in the more advanced stages of fibrosis and inflammation. There was no correlation between the gene expression and the serum viral load. Regarding the initial METAVIR scale scores, liver transaminase levels were lower in patients with advanced fibrosis when correlated with TLR3 and IFNL3 gene expressions. The results suggest that in the early stages of the development of hepatic fibrosis, TLR3 and IFN-λ3 play important roles in the antiviral response and in the modulation of the tolerogenic liver environment because there is a decrease in the intrahepatic expressions of TLR3 and IFNL3 in the advanced stages of fibrosis, probably due to viral evasion mechanisms.


2019 ◽  
Vol 10 ◽  
Author(s):  
Valli De Re ◽  
Maria Lina Tornesello ◽  
Mariangela De Zorzi ◽  
Laura Caggiari ◽  
Francesca Pezzuto ◽  
...  

2017 ◽  
Vol 21 (6) ◽  
pp. 1113-1123
Author(s):  
Kazuaki Okino ◽  
Yuki Okushi ◽  
Kiyotaka Mukai ◽  
Yuki Matsui ◽  
Norifumi Hayashi ◽  
...  

Hepatology ◽  
1998 ◽  
Vol 28 (3) ◽  
pp. 810-814 ◽  
Author(s):  
Roberto Burioni ◽  
Paola Plaisant ◽  
Aldo Manzin ◽  
Domenico Rosa ◽  
Valeria Delli Carri ◽  
...  

2007 ◽  
Vol 22 (1) ◽  
pp. 74-79 ◽  
Author(s):  
Neri Sergio ◽  
Travali Salvatore ◽  
Bertino Gaetano ◽  
Pulvirenti Davide ◽  
Italiano Claudio ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document